20:38 , Mar 30, 2017 |  BC Innovations  |  Emerging Company Profile

Unlocking liver regeneration

Although many acute and chronic liver diseases eventually cause liver failure, the only approved treatment is liver transplantation. HepaRegeniX GmbH is developing MKK4 inhibitors to unlock the regenerative capacity of endogenous hepatocytes to treat end-stage...
01:48 , Dec 3, 2015 |  BC Extra  |  Financial News

Kesios' series A brings L19M

Kesios Therapeutics Ltd. (London, U.K.) closed a L19 million ($28.5 million) series A round led by existing investor Imperial Innovations Group plc (LSE:IVO). New investors SV Life Sciences and Abingworth also participated. Chairman and newly...
08:00 , Nov 6, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Multiple myeloma (MM) Growth arrest and DNA-damage-inducible 45b (GADD45B); mitogen-activated protein kinase kinase 7 (MAP2K7; MKK7) Studies...
07:00 , Oct 20, 2014 |  BioCentury  |  Emerging Company Profile

Kesios: Reactivating apoptosis

Kesios Therapeutics Ltd. is targeting a downstream component of the NF-kappa B signaling pathway that is overexpressed in multiple myeloma cells with the aim of providing efficacy similar to other MM therapies, but with a...
08:00 , Dec 15, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Mitogen-activated protein kinase kinase 4 (MAP2K4; MKK4); MAP2K7 (MKK7) Cell culture and mouse...
07:00 , Mar 31, 2008 |  BioCentury  |  Regulation

EGFR pathway

EGFR pathway Vectibix panitumumab and other epidermal growth factor (EGF) receptor inhibitors are intended to prevent the growth and survival of cells that express EGFR. However, the Ras pathway is downstream of EGFR, so if a...
07:00 , Oct 5, 1998 |  BC Week In Review  |  Company News

Signal Pharmaceuticals, University of Massachusetts Medical School deal

Signal received exclusive rights to the school's U.S. Patent No. 5,736,381 covering MKK6 and MKK7, two proteins involved in modulating the p38 and JNK gene regulation pathways, and JIP-1, a JNK regulatory protein. The...